Journal article

Cost-effectiveness of lowering blood pressure with a fixed combination of perindopril and indapamide in type 2 diabetes mellitus: an ADVANCE trial-based analysis

Paul P Glasziou, Philip Clarke, Jan Alexander, Mohana Rajmokan, Elaine Beller, Mark Woodward, John Chalmers, Neil Poulter, Anushka Patel

Medical Journal of Australia | WILEY | Published : 2010


OBJECTIVE: To determine the cost-effectiveness of routine administration, irrespective of blood pressure (BP), of a fixed-dose combination of perindopril and indapamide to patients with type 2 diabetes mellitus. DESIGN, SETTING AND PARTICIPANTS: Prospective cost-effectiveness analysis within the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) trial, an international, multicentre, randomised controlled trial of 11,140 participants with type 2 diabetes randomly allocated to receive perindopril plus indapamide (4 mg-1.25 mg/day) or placebo. MAIN OUTCOME MEASURES: Health-related quality-of-life measured by the EuroQol-5D, resource utilisation, a..

View full abstract


Funding Acknowledgements

We thank Peter Walker and 3M Australia for granting us use of their software or our analyses, the ADVANCE centres, and the ADVANCE trial patients The ADVANCE trial is funded by grants from the National Health and Medical Research Council of Australia and Institut de Recherches Internationales Servier Members of the ADVANCE Collaborative Group are fully listed in The Lancet<SUP>9</SUP> Neil Poulter rece ved funding from the UK National Institute for Health Research Biomedical Research Centre funding scheme The George Institute provided institutional grants for work on the substudy by Paul Glasziou, Philip Clarke, Janet Alexander, Mohana Rajmokan, and Elaine Beller John Chalmers and Philip Clarke received institutional research grants from Servier